3 results
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.
Approved WMOCompleted
To assess the efficacy of GV-971 compared with placebo on cognition and global function in participants with mild to moderate Alzheimer's disease (AD).
Approved WMOPending
To assess the diagnostic performance of PCCT to identify the luminal patency compared with ICA as the reference standard, in patients with a history of PCI with stent placement and to assess image quality by applying different image reconstruction…